684 - Amlitelimab (an anti-OX40 ligand antibody) vs placebo in patients with moderate-to-severe atopic dermatitis: study design of phase 3 OCEANA clinical trials COAST 1/2, SHORE, AQUA, and ESTUARY

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

British Journal of Dermatology

Topics

Medicine

Pathology

Physiology

Dermatology

Internal Medicine

Show all topics

DOI

10.1093/bjd/ljae266.058